Gene Editing Market Size

Global Gene Editing Market Overview

The Gene Editing Market size was valued at USD 7.19 billion in 2023 and is projected to grow from USD 8.69 Billion in 2023 to USD 39.79 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 20.94% during the forecast period (2024 - 2032). The growing number of strategic initiatives and increasing funding for genetic research are major factors driving the market growth.

Korean-based biotechnology company GenKOre, Inc. specializes in hypercompact CRISPR-Cas tools and has entered into a strategic collaboration for developing gene-editing therapeutics in vivo. It relied on GenKOre’s TaRGET platform and its proprietary CRISPR-Cas technology.

The Therapeutic Oligonucleotide Manufacturing facility at Coralville, Iowa, was announced as completed by Integrated DNA Technologies (IDT), one of the world's principal providers of genomic solutions.

In January 2024, Danaher Corporation agreed with the Innovative Genomics Institute (IGI) to collaborate. The aim is to apply the different technologies that Danaher possesses and IGI’s academic skills to develop therapies based on CRISPR for rare genetic disorders.

A collaboration agreement between Cellectis and AstraZeneca for accelerated development of advanced cancer and immunology therapy was concluded in November 2023.

To create epigenetic drugs reliant on Sangamo's Zinc Finger Proteins (ZFPs), Sangamo Therapeutics partnered with Chroma Medicine in July 2023. For targets outside the central nervous system, Chroma will evaluate ZFPs against specific licenses that can be developed or commercialized.

In May 2023, a research program at Lewis Katz School of Medicine at the University of Nebraska Medical Center reported successful treatment of HIV infection in animals utilizing CRISPR.

LGC acquired Rapid Genomics in April 2022 as part of its NGS application enhancement strategy aimed at high-throughput genotyping for the agrigenomics market.

New Biologix SA emerged from hiding as a technological innovation firm establishing an unrivaled revolutionary platform used for sophisticated production cell lines used in gene and cell therapy applications. The company intends to use recombinant adeno-associated viral vectors to generate advanced therapy medicinal products as an alternative DNA-based process addressing critical manufacturing bottlenecks.

In April 2023, Ayana Bio, a Boston-based provider of plant cell technologies, announced the first-ever launch of sleep, mood, and immune support formulas as supplements using plant cell-cultivated ingredients like echinacea and lemon balm.

In October 2022, Cytiva acquired CEVEC Pharmaceuticals, one of Germany’s top suppliers of high-performance cell-line development and viral vector manufacturing technology. This acquisition will solidify Cytiva’s position as an industry leader in biomanufacturing solutions.

Gene Editing Market Trends

• Growing number of Strategic initiatives

Genomic editing refers to the strategies and techniques used to modify the genetic information of any living organism. Genome editing involves the modification of genes in multiple locations using recombinant technology, which increases insertion precision and decreases cell toxicity. It is a collection of technologies that allow scientists to alter an organism's DNA. These technologies enable adding, deleting, or modifying genetic material at specific locations within the genome. Rise in the number of strategic initiatives in the form of mergers, acquisitions, product approval, collaborations, and partnerships among the players to gain a competitive edge and offer advanced treatment options for genomic editing is the major factor drive the growth of market. 

For instance, in April 2022, Thermo Fisher Scientific (US) launched a new GMP-manufactured Gibco CTS TrueCut Cas9 Protein, as high-quality auxiliary materials and documentation are essential, as researchers using genome editing techniques transition from basic research to therapeutic settings. Gibco CTS TrueCut Cas9 Protein is an attractive option for CAR T-cell therapy research employing CRISPR-Cas9 genome editing since it consistently achieves high editing efficiency in all studied cell lines and better than 90% efficiency in human primary T-cells. Similarly, in February 2022, Intellia Therapeutics, Inc. (US) and Regeneron Pharmaceuticals, Inc. (US) announced the positive interim data from an ongoing Phase I clinical study of their lead in vivo genome editing candidate, NTLA-2001 (Investigational Crispr Therapy for Transthyretin (Attr) Amyloidosis). 

Moreover, in February 2022, GenScript Biotech Corporation (US) launched its new CRISPR Genome Editing Cell Line Engineering Service, which enables scientists to create custom cell lines for research and therapeutic applications. The service utilizes GenScript's proprietary CRISPR/Cas9 technology and experienced team of scientists to deliver precise and efficient genome editing. Additionally, it will also expand the company’s position and its commitment to delivering therapeutic applications across the world.

Gene Editing Market Segment Insights

Gene Editing Technology Insights

By Technology the market is classified into CRISPR, TALEN, ZFN, antisense, and others. The CRISPR segment held the majority share in 2022 in the Gene editing Market revenue due to its wide range of applications in vivo to fix the target gene and ex vivo to rewire & redirect cells for genetic diseases and immuno-oncology autoimmune diseases. Furthermore, the increasing number of applications for CRISPR technology an rise in adoption key strategies by major players is expected to drive demand for gene editing over the forecast period. For instance, in 2024, Drug discovery company IRBM (Rome) has signed a non-exclusive agreement granting access to ERS Genomics’ CRISPR/Cas9 patent portfolio. The Italian CRO offers expertise ranging from target validation and hit finding to preclinical candidate nomination across various therapeutic areas, including oncology, infectious diseases and neuroscience. The company has contributed to the discovery and development of four marketed therapeutics for HIV, HCV, ovarian cancer and cutaneous T-cell lymphoma.

Gene Editing Application Insights

By application the market is classified into genetic engineering and clinical application. The genetic engineering segment has dominated the market in 2023, as it allows scientists to directly manipulate the genetic material of an organism to achieve desired traits or characteristics. This technology offers a precise and efficient way to edit genes, which can lead to advancements in agriculture, medicine, and other industries.

Gene Editing Method Insights

Based on Type, the Gene Editing Market is bifurcated into Ex-vivo and In-Vivo products. The in vivo segment has dominated the market in 2023, due to their ability to directly deliver genetic editing tools into living organisms, allowing for targeted and efficient gene editing. This method has gained popularity in recent years as it offers several advantages over traditional methods such as ex vivo delivery. Additionally, In vivo delivery methods are being used in a wide range of applications, including gene therapy, drug development, and agricultural biotechnology. These methods are particularly valuable in the field of gene therapy, where they have shown promising results in treating various genetic disorders such as cystic fibrosis, sickle cell anemia, and muscular dystrophy. Overall, the increasing adoption of in vivo delivery methods is driving the growth of the genetic editing market by providing more effective and efficient ways to edit genes in living organisms.

GENE EDITING MARKET SIZE, BY TYPE, 2019 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Gene Editing End User Insight

By end user, the market is bifurcated into biotechnology and pharmaceutical companies, contract research organizations (CROs), and academic & government research institutes. The biotechnology and pharmaceutical companies’ segment have dominated the market in 2023 and is projected to be the fastest-growing segment during the forecast period, 2024-2032. This is due to the increase in funding for gene editing for the development of therapeutic products. Some major companies that raised funding for gene editing platform include Beam Therapeutics (US), which raised USD 135 million on March 2019, Graphite Bio (US), which raised USD 195 million in March 2021, and Caribou Biosciences (US), which raised USD 169 million in March 2021.

Furthermore, in September 2022, Integrated DNA Technologies Inc (US) expands customization options for Alt-R Custom CRISPR gRNA Libraries for drug discovery. This expansion allows researchers to quickly assess new therapeutic options.

Gene Editing Regional Insight

By Region, the market is classified into North America, Europe, Asia-Pacific, and Rest of the World.

The North America gene editing market held the largest share in the market. This is attributed to the increase in the prevalence of chronic disease, a growing preference for gene therapies, an increase in private and public sector funding, and rapid advancements in sequencing and gene editing technologies are driving the market for gene editing in the North America region. For instance, in March 2021, Scientists at the University of California (UC), San Francisco, UC Berkeley, and UC Los Angeles received the Food and Drug Administration's approval to jointly launch an early phase, first-in-human clinical trial of a gene correction therapy in sickle cell disease patients using the patient's blood-forming stem cells. Furthermore, according to National Centre for Advancing Translational Sciences reports from June 2022, the National Institutes of Health (NIH) Somatic Cell Gene Editing (SCGE) Programme has given 24 new funds to researchers in the US and Canada. Over the next four years, the SCGE Programme will award a total of USD 89 million in advance gene editing grants.

Asia Pacific is expected to be the fastest-growing region in the gene editing market due to factors such as increasing investments in research and development, advancements in technology, and growing prevalence of genetic disorders in the region. One of the key drivers of growth in the Asia Pacific gene editing market is the increasing focus on personalized medicine and precision medicine in countries like China, Japan, and South Korea. These countries have been making significant investments in genomics research and precision medicine initiatives, which is driving the demand for gene editing technologies.

Additionally, the region has a large population with a high prevalence of genetic disorders, such as thalassemia, sickle cell anemia, and various types of cancer. This has created a significant need for advanced gene editing solutions to develop potential treatments and therapies for these conditions. Furthermore, the Asia Pacific region is home to a thriving biotechnology and pharmaceutical industry, which is further boosting the growth of the gene editing market. Companies in countries like China and India are increasingly focusing on developing innovative gene editing technologies and therapies, which is driving the market growth in the region.

Overall, the Asia Pacific region offers immense growth opportunities for the gene editing market, and with the advancements in technology and increasing investments in research and development, the market is expected to witness rapid growth in the coming years.

Gene Editing Key Market Players & Competitive Insights

The key market players in the gene editing industry include companies like Bio-Rad Laboratories, Inc, Lonza GenScript, Sangamo Therapeutics, and Thermo Fisher Scientific. These companies are at the forefront of developing cutting-edge gene-editing technologies and are continuously investing in research and development to expand their product offerings and market reach.

The gene editing market is highly competitive, with a growing number of players entering the space and large investments being made in developing new and innovative gene-editing technologies. Additionally, partnerships and collaborations between industry players and academic institutions are becoming increasingly common, driving further innovation in the field. For instance, in November 2021, GenScript launched the GenWand Double-Stranded DNA (dsDNA) service for the manufacture of CRISPR knock-in homology-directed repair (HDR) templates in T-cell engineering.

companies in the gene editing industry are also focused on obtaining regulatory approvals for their products and expanding their presence in key markets worldwide. The competition is intense, with players vying for market share and striving to differentiate themselves through technological advancements, strategic partnerships, and strong intellectual property portfolios.

Overall, the gene editing market is dynamic and rapidly evolving, with key players working tirelessly to stay ahead of the curve and shape the future of gene editing technologies.

Key Companies in the Gene Editing Market include.

• GE Healthcare (US)


• Thermo Fisher Scientific Inc (US)


• Bio-Rad Laboratories, Inc (US)


• Lonza (Switzerland)


• GenScript (US)


• Horizon Discovery Ltd (UK)


• OriGene Technologies, Inc (US)


• Integrated DNA Technologies, Inc (US)


• New England Biolabs, Inc (US)


• Sangamo Therapeutics (US)

Gene Editing Industry Developments

September 2022: Integrated DNA Technologies Inc (US) expands customization options for Alt-R Custom CRISPR gRNA Libraries for drug discovery. This expansion allows researchers to quickly assess new therapeutic options.

July 2020: Horizon Discovery Group plc (UK) announced an agreement with TrueBinding, Inc a biopharmaceutical company, has signed an agreement of commercial licenses for Horizon’s cGMP compliant CHOSOURCE platform. TrueBinding used the platform for the development and commercialization of many biotherapeutic products for utilize in immuno-oncology and other diseases.

November 2021: GenScript (US) has launched the Gen Wand Double-Stranded DNA (dsDNA) service for the manufacture of CRISPR knock-in homology-directed repair (HDR) templates in T-cell engineering.

April 2019: GenScript (US) launched a Single-stranded DNA Service for CRISPR-based gene editing. The newly launched service provides researchers with high-quality, pure ssDNA for CRISPR-based gene insertion, with the goal of accelerating the development of gene therapy, cell therapy, and transgenic animal models for cancer research and treatment.

Gene Editing Market Segmentation

Gene Editing Technology Outlook

• CRISPER


• TALEN


• ZFEN


• Antisense


• Other

Gene Editing Application Outlook

• Genetic Engineering
  
  
  
  • Cell line engineering
  
  
  • Animal genetic engineering
  
  
  • Plant genetic engineering
  
  
  • Others
  
  
  
  


• Clinical applications
  
  
  
  • Diagnostics
  
  
  • Therapy Development
  
  
  
  


• Others

Gene Editing Method Outlook

• Ex-vivo


• In-vivo

Gene Editing End-Users Outlook

• Biotechnology and Pharmaceutical Companies


• Contract Research Organizations (CROs)


• Academic and Government Research Institutes

Gene Editing Regional Outlook

North America

• US


• Canada

Europe

• Germany


• France


• UK


• Italy


• Spain


• Rest of Europe

Asia-Pacific

• China


• Japan


• India


• South Korea


• Australia


• Rest of Asia-Pacific

Rest of the World

• Middle East


• Africa